Fig 2: Analysis of concomitant mutations in KRAS, NRAS, BRAF and PIK3CA. (A) Venn diagram showing the distribution of single and concomitant mutations in the KRAS, NRAS, BRAF and PIK3CA genes. (B) Frequency of mutations in KRAS, NRAS, BRAF and PIK3CA exons in patients with CRC. The mutations in all exons are listed in the figure. Among them, the frequency of KRAS exon 2 mutations was the highest (55.8%), and concomitant mutations accounted for 7.7% (8/104) of mutations.

Fig 3: Kaplan-Meier curves for patients with colorectal cancer with and without KRAS mutations. (A) Comparison of overall survival, showing a significant difference (P=0.0246). (B) Comparison of disease-free survival, showing a significant difference (P=0.0016). HR, hazard ratio.

Fig 4: Comparison of RNF215 expression in the KRAS, NRAS, BRAF and PIK3CA mutant vs. WT CRC groups in 182 CRC patients. (A) Expression of RNF215 in KRAS mutant vs. WT CRC patients (P=0.8345). (B) Expression of RNF215 in NRAS mutant vs. WT CRC patients (P>0.9999). (C) Expression of RNF215 in BRAF mutant vs. WT CRC patients (P=0.4950). (D) Expression of RNF215 in PK3CA mutant vs. WT CRC patients (P>0.9999). RNF215, ring finger protein 215; CRC, colorectal cancer; WT, wild-type.

Fig 5: PCR mutation curves for the KRAS, NRAS, BRAF and PIK3CA genes in patients with colorectal cancer. (A) KRAS-EXON2-G13D mutation. (B) NRAS-EXON2-G12 mutation. (C) BRAF-EXON15 mutation. (D) PIK3CA-EXON10 mutation. (E) Concomitant KRAS-EXON2 and NRAS-EXON2 mutations. (F) Concomitant KRAS-EXON3 and PIK3CA-EXON10 mutations.